Kiertscher, Sylvia M <br/><br/>
Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients.  [electronic resource] 

 -  International journal of cancer  Nov 2003 
 - 256-61 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0020-7136 
<br/><br/><label>Standard No.: </label>10.1002/ijc.11379  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, CD--blood<br/>Case-Control Studies<br/>Dendritic Cells--immunology<br/>Granulocyte-Macrophage Colony-Stimulating Factor--administration & dosage<br/>HLA-DR Antigens--immunology<br/>Humans<br/>Immunotherapy<br/>Interleukin-4--administration & dosage<br/>Lymphocytes--immunology<br/>Monocytes--immunology<br/>Neoplasms--blood<br/>Neoplastic Cells, Circulating<br/>Phenotype<br/>Recombinant Proteins<br/>Th2 Cells--immunology